CASIRIVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Possibly Marketed Outside US

First approved in 2020

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 16:04:57 GMT 2023` Edited by `admin` on `Sat Dec 16 16:04:57 GMT 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	J0FI6WE1QN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

REGN-10933

Preferred Name

English

CASIRIVIMAB

Official Name

English

CASIRIVIMAB [USAN]

Common Name

English

Casirivimab [WHO-DD]

Common Name

English

CASIRIVIMAB [JAN]

Common Name

English

IMMUNOGLOBULIN G1, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN) (HUMAN MONOCLONAL REGN10933 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN10933 .KAPPA.-CHAIN, DIMER

Common Name

English

REGN10933

Code

English

casirivimab [INN]

Common Name

English

Code System Code Type Description

INN

11861

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

SMS_ID

300000023252

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

RXCUI

2465242

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

DAILYMED

J0FI6WE1QN

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

NCI_THESAURUS

C177087

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

CAS

2415933-42-3

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

USAN

HI-236

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

FDA UNII

J0FI6WE1QN

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

LACTMED

Casirivimab

Created by admin on Sat Dec 16 16:04:57 GMT 2023 , Edited by admin on Sat Dec 16 16:04:57 GMT 2023

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_147	2_203
2_223	4_214
2_264	2_324
1_147	1_203
2_370	2_428
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194
1_223	3_214
1_229	2_229
1_232	2_232
1_264	1_324
1_370	1_428

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_300

Related Record Type Details


					0EO1SV3LKY

SPIKE-1 PROTEIN SARS-COV-2

TARGET -> INHIBITOR

Comments:

In blocking studies, REGN10933, REGN10987, and REGN-COV2 mediated concentration-dependent blockade of SARS-CoV-2 RBD binding to human ACE2 with IC50 values in the subnanomolar range.

Interaction Type:

IN-VITRO

Qualification:

IC50

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					J0FI6WE1QN

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL